How long does it take for brigatinib to be effective?

Brigatinib is a tyrosine kinase inhibitor mainly used to treat anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer. As for how long it takes for brigatinib to exert its effect, this is not a fixed time period, but varies depending on individual differences.

Usually, patients begin to see results after taking brigatinib for 1-2 weeks, but this is not absolute because each patient's condition is different and their sensitivity to the drug is also different. Studies have shown that most patients can evaluate the initial efficacy after taking brigatinib for 1 month.

In an advanced disease refractory to ALK or other ALK tyrosine kinase inhibitors< In a study of the efficacy and safety of patients with span>ALKpositive non-small cell lung cancer, the estimated median progression-free survival for patients treated with brigatinib was 24 months.

Another clinical study showed that in patients with ALK mutation-positive advanced non-small cell lung cancer who had not previously received an ALK inhibitor, approximately 80% of patients achieved a clinical response within 3 months of starting treatment.

The efficacy of brigatinib may be significantly increased when combined with certain drugs, such as cetuximab. For example, the overall objective response rate of patients treated with brigatinib combined with cetuximab can reach 60%. While patients are taking brigatinib, they should undergo regular examinations to evaluate the efficacy of the drug. If any adverse reactions or signs of disease progression occur, report them to your doctor promptly.

In summary, the time it takes for brigatinib to exert its efficacy varies among individuals and may range from weeks to months. It is important that patients work closely with their doctor to take their medications on time, have regular checkups to assess effectiveness, and promptly report any treatment-related problems. Through scientific treatment plans and continuous monitoring, the efficacy of brigatinib can be maximized and the quality of life and survival of patients can be improved.

References:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brigatinib-alk-positive-metastatic-nsclc